Document is current
Any future updates will be listed below
-
Authors
Ikenaga, Naoki
Hashimoto, Tadayoshi
Mizusawa, Junki
Kitabayashi, Ryo
Sano, Yusuke
Fukuda, Haruhiko
Nakata, Kohei
Shibuya, Kazuto
Kitahata, Yuji
Takada, Minoru
Kamei, Keiko
Kurahara, Hiroshi
Ban, Daisuke
Kobayashi, Shogo
Nagano, Hiroaki
Imamura, Hajime
Unno, Michiaki
Takahashi, Amane
Yagi, Shintaro
Wada, Hiroshi
Shirakawa, Hirofumi
Yamamoto, Naoto
Hirono, Seiko
Gotohda, Naoto
Hatano, Etsuro
Nakamura, Masafumi
Ueno, Makoto
,
-
Funding
Funding for this research was provided by:
National Cancer Center Research and Development Funds (2020-J-3, 2023-J-03, 2020-J-3, 2023-J-03)
- License Information
-
More Information
Article History
Received: 30 November 2023
Accepted: 5 February 2024
First Online: 19 February 2024
Declarations
:
: All patients receive verbal and written information and provide their written informed consent before enrolment. This study is conducted in accordance with the ethical principles stipulated in the “Declaration of Helsinki” (revised October 2013) and “Clinical Trials Act” (announced April 14, 2017, enacted April 1, 2018) established by Japan’s Ministry of Health, Labour, and Welfare. This study was approved by the National Cancer Center Hospital Central Review Board on January 26, 2023 (approval number: T2022007).
: Not Applicable.
: Dr. Mizusawa reports grants from Ministry of Health, Labour and Welfare, Japan, during the conduct of the study; lecture fees from Taiho Pharmaceutical and Chugai Pharmaceutical outside the submitted work; his spouse is an employee of Pfizer; Dr. Fukuda reports lecture fees from Kyowa Kirin Co., Ltd., Chugai Pharmaceutical, and CMIC Co., Ltd. outside the submitted work; Dr. Unno reports grants from Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, and Asahi-Kasei Pharmaceutical during the conduct of the study; Dr. Nakamura reports grants from Taiho Pharmaceutical, Chugai Pharmaceutical, Covidien Japan Inc. during the conduct of the study.
